Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Combination of venetoclax and standard therapies shows promise in high-risk myeloid blood cancers

The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.

7 Dec 2020

Donor stem cell transplant can improve survival rates for older patients with MDS, study shows

A new clinical trial offers the most compelling evidence to date that a donor stem cell transplant can improve survival rates for older patients with higher-risk myelodysplastic syndrome (MDS), Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology Annual Meeting.

5 Dec 2020

Study sheds light on the high burden of late effects among young survivors of acute myeloid leukemia

Adolescent and young adult (AYA) patients treated for acute myeloid leukemia (AML) have a high risk of developing several long-term health complications, a study led by UC Davis Comprehensive Cancer Center researchers has found.

9 Nov 2020

Beat AML trial achieves primary endpoint

Patients participating in The Leukemia & Lymphoma Society's (LLS) groundbreaking precision medicine Beat AML Master Clinical Trial had superior outcomes compared to acute myeloid leukemia (AML) patients who opted for standard chemotherapy treatment, according to findings published today in the prestigious Nature Medicine journal.

28 Oct 2020

Advancements in research on cancer signal transduction and treatment

Cancer is driven by numerous genetic and epigenetic changes occurring at the cellular level. These changes drive normal cells to proliferate and escape processes that usually regulate their survival and migration.

27 Oct 2020

UVA research sheds light on how cancer remodels our chromosomes

Cancer remodels the architecture of our chromosomes so the disease can take hold and spread, researchers at the University of Virginia have revealed.

27 Oct 2020

Study analyzes link between clonal hematopoiesis and treatment-related blood cancer risk

In recent years, improvements in cancer therapy have led to a significant increase in cancer survivorship. Experts estimate that by 2022, the United States will have 18 million cancer survivors, but a subset of those survivors will have long-term health problems to be addressed.

27 Oct 2020

SARS-CoV-2 infection of carotid arteries may explain vascular involvement in COVID-19

A new study published on the preprint server bioRxiv in October 2020 shows that the virus causing COVID-19, namely, SARS-CoV-2, produces replicative infection in the carotid arteries and affects the vascular responses. This could have a profound bearing on the understanding of the disease and its clinical treatment.

14 Oct 2020

Researchers identify a potential target for small cell lung cancer

The cover for issue 39 of Oncotarget features Figure 4, "Apoptosis assay of NRXN1-targeted ADC at IC50 dose calculated by growth inhibition curves," by Yotsumoto, et al. which reported that the authors identified transmembrane proteins overexpressed specifically in SCLC with little or no expression in normal tissues and decided to focus on the cell adhesion molecule neurexin-1.

1 Oct 2020

MD Anderson and Astex Pharmaceuticals partner to accelerate clinical evaluation of leukemia therapies

The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex's pipeline of products for patients with certain types of leukemia, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).

8 Sep 2020

Researchers identify new mechanism that causes leukemia

Every year, 1.1 million new cases of blood cancers are diagnosed worldwide. Presently, chemotherapy remains the most common and effective course of treatment.

13 Aug 2020

Combination regimen improves overall survival in certain patients with AML

A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.

12 Aug 2020

Powerful treatment for IPF stops dangerous scar formation in mouse lungs

A pre-clinical study led by scientists at Cincinnati Children's demonstrates that in mice the drug barasertib reverses the activation of fibroblasts that cause dangerous scar tissue to build up in the lungs of people with idiopathic pulmonary fibrosis (IPF).

6 Aug 2020

ASH publishes new guidelines to help tailor treatment for older adults with acute myeloid leukemia

Today, ASH published new guidelines to help older adults with acute myeloid leukemia (AML) and their health care providers make critical care decisions, including if and how to proceed with cancer treatment and the need for blood transfusions for those in hospice care.

6 Aug 2020

Study could refine treatment recommendations for younger adult patients with acute leukemia

The findings of a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) could refine an important set of prognostic and treatment recommendations for younger adult patients with acute myeloid leukemia (AML.

6 Aug 2020

Study reveals impact of TP53 gene mutations on MDS severity

Considered the "guardian of the genome," TP53 is the most commonly mutated gene in cancer. TP53's normal function is to detect DNA damage and prevent cells from passing this damage on to daughter cells.

3 Aug 2020

Study sheds light on potential new treatment approach in AML patients

Tyrosine kinases are protein enzymes that have many functions within cells, including cell signaling, growth, and division. Sometimes these enzymes can be overactive, which helps cancer cells survive and multiply.

31 Jul 2020

Researchers identify specific target sites for DNA methylases

DNA methylation performs an essential function in mammalian ontogeny. It is also known that abnormalities in this process cause the development of cancers such as leukemia.

22 Jul 2020

Mapping immune landscape of hematological malignancies may help improve cancer therapies

Activating the immune system of the body is a promising form of treatment for cancer. Researchers at the University of Helsinki and Helsinki University Hospital as well as the University of Eastern Finland mapped out the immune landscape of hematological malignancies in a dataset covering more than 10,000 patients to identify drug targets and patient groups which could potentially benefit from immunotherapies.

9 Jul 2020

New nanoconjugate blocks dissemination of tumor cells in animal models of acute myeloid leukemia

The nanoparticle targets only leukemic cells and therefore would reduce the severe adverse effects of current treatments.

9 Jul 2020

Acute Myeloid Leukemia News and Research

Further Reading

Combination of venetoclax and standard therapies shows promise in high-risk myeloid blood cancers

Donor stem cell transplant can improve survival rates for older patients with MDS, study shows

Study sheds light on the high burden of late effects among young survivors of acute myeloid leukemia

Beat AML trial achieves primary endpoint

Advancements in research on cancer signal transduction and treatment

UVA research sheds light on how cancer remodels our chromosomes

Study analyzes link between clonal hematopoiesis and treatment-related blood cancer risk

SARS-CoV-2 infection of carotid arteries may explain vascular involvement in COVID-19

Researchers identify a potential target for small cell lung cancer

MD Anderson and Astex Pharmaceuticals partner to accelerate clinical evaluation of leukemia therapies

Researchers identify new mechanism that causes leukemia

Combination regimen improves overall survival in certain patients with AML

Powerful treatment for IPF stops dangerous scar formation in mouse lungs

ASH publishes new guidelines to help tailor treatment for older adults with acute myeloid leukemia

Study could refine treatment recommendations for younger adult patients with acute leukemia

Study reveals impact of TP53 gene mutations on MDS severity

Study sheds light on potential new treatment approach in AML patients

Researchers identify specific target sites for DNA methylases

Mapping immune landscape of hematological malignancies may help improve cancer therapies

New nanoconjugate blocks dissemination of tumor cells in animal models of acute myeloid leukemia

Passing on Polycystic Ovary Syndrome: Health risks for male offspring of women with PCOS

Top-Down Proteomics: Bridging the Genotype-to-Phenotype Gap

Bridging the Gap between Academia and Industry: The Power of Collaboration in Life Sciences

Latest News